The urgent unmet need in IBD and the impact on patients

Crohn's disease and ulcerative colitis are common inflammatory bowel diseases.
They affecting nearly 1 in 100 people in the UK, across Europe and N America, with rapidly rising incidence rates across the world.
Impact on patients can be very profound - physical symptoms, psychosocial features and the long term complications of the disease and the drugs. But it is the impact on everyday life that can be most significant for the individual.
We have a series of unmet needs in 2022 from raising awareness and ensuring equity of care to the need for new therapies, better monitoring systems and a holistic approach that results in meaningful healing.
Video Editing by @IBDNathan Nathan Constantine-Cooke
Graphic design by ‪@ErikRva‬
charlielees.substack.com/ ATOMIC IBD
charlielees.com/
www.predicct.co.uk/
czcams.com/channels/hUG.html...
crohnsandcolitis.org.uk/
#atomicIBD #crohnsdisease #crohn #IBD #inflammatoryboweldisease #colitis #ulcerativecolitis #UC @crohnsandcolitisuk
PROFESSOR CHARLIE W LEES FRCP(Ed) PhD
Charlie is Professor of Gastroenterology at the University of Edinburgh, a UK Research and Innovation Future Leaders Fellow (UKRIFLF) and Consultant Gastroenterologist in the Edinburgh IBD Unit. His clinical, teaching and research interests have been focused on inflammatory bowel disease (IBD) since 2003. He was awarded his PhD in the Genetics of IBD and the prestigious UEG Rising Star award in Gastroenterology, both in 2009. Following this he spent 10 years working as a full-time consultant gastroenterologist leading an increasingly busy and complex IBD clinic.
In 2019 Charlie was awarded a personal fellowship from UKRI - worth £1.7m - that enabled his transition to full-time academic gastroenterology. His research team are based in the Centre for Genomics and Experimental Medicine within the Institute of Genetics and Cancer in Edinburgh.
Charlie’s core mission is to improve outcomes for people living with IBD.
His team are working on predicting outcomes in IBD, using routinely collected NHS data (the Lothian IBD Registry) and dedicated multi-modal prospective cohorts to build predictive models.
He is Chief Investigator of the PREdiCCt study, which has recruited 2650 patients in clinical remission with detailed baseline phenotyping (clinical, psycho-social, lifestyle, environmental, dietary, microbiome and genomics) and a minimum of 24 months longitudinal follow-up.
Conflicts of Interest
Professor Charlie Lees has acted as a speaker and/or consultant to Abbvie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Novartis, Sandoz, Celltrion, Fresnius Kabi, Tillotts, Trellus Health and Iterative Scopes.

[@dalehawkins-lw6rc]

(FACTS OVA FEELINGS). Wen WEE have a Desperate Un- met Need Often watt Wee r Attracted to in another Person the Part of Them Wee Think can Meet hOUR Need is Simply a Coping Mechanism of Theirs rather than an Authentic Expression of who They Really R

[@SuperM0th]

Thank you 🙏

[@stuartwalker341]

I hope research progresses towards meaningful alternatives to drugs. They are so costly. Some doctors have told me that the goal with medication is to get me so I can eat whatever I want. I don't want to eat whatever. I want to eat food that is good for my condition. I really want to know about any research on how much can be managed with lifestyle changes like diet, exercise, sleep, supplements to address deficiencies, stress management, and actively cultivating a better gut microbiome.

[@nolungesplease2945]

I have it.
I am on a waiting list see a specialist. The specialist is the only one thay can prescribe the medication.
Unfortunately for me I could be waiting years. Because The waiting list is so long. They can't give me a date or time frame.
I don't know what to do while waiting.
What can I do now without medication?
I'm in pain and I am exhausted all the time. I have a 2 and 5 year old to look after. I just want my energy back.